Biotech Stocks

Cronos (CRON) Stock Looks Chronically Overpriced

Cronos (CRON) stock spent most of last year underwater from its IPO price. Of course, after Altria announced a $1.

Teva Stock Slips on Back of Weak 2019 Outlook; Analysts Weigh In

You know there was some bad news with a company’s quarterly update when the stock tanks after the results are announced. That’s what …

Don’t Say Bye Bye to Intercept (ICPT) Stock, Say Buy Buy

With Intercept (ICPT) preparing to release Phase 3 results from its REGENERATE study in Non-Alcoholic Steatohepatitis (NASH) patients, Gilead (GILD) announced yesterday that its top late-stage NASH drug …

MacroGenics (MGNX) Stock Fires on All Cylinders; Analysts Weigh In

It’s a very rewarding trading day for investors in MacroGenics (MGNX) with shares up over 120%, making the stock Wall Street’s bull of …

Trevena (TRVN) Stock Roars Back to Life; Analysts Dive In

Shares of Trevena (TRVN) came back to life. The struggling biotech stock took a rare leap upward last week, as well as today, as resolution …

Evolus (EOLS) Stock Just Got a Major Face-Lift; Mizuho Analyst Weighs In

Congrats. Evolus (EOLS) is the first company to win FDA approval for a neurotoxin that is considered biosimilar to branded Botox for the …

Teva Stock Gets a Thumbs Up from Merrill Lynch Ahead of Earnings

The turnaround at Teva Pharmaceutical Industries (TEVA) remains on schedule. Investors appear satisfied that CEO Kare Schultz is making enough progress in battling …

Amarin (AMRN): New Survey Offers Insight Into Vascepa Market Opportunity

Amarin’s (AMRN) Vascepa is currently approved to treat around 3.8 million Americans with high triglycerides, as an adjunct to diet.

Is It Too Late to Join the OncoCyte (OCX) Stock Party? Analyst Weighs In

Investors love healthcare stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Shares of …

Should You Buy Amarin (AMRN) Stock? 4 Pros, 4 Cons

Year-to-date, Amarin (AMRN) stock is up nearly 20% due to Pfizer buyout chatter. According to rumors, the pharma giant is interested in making …